Dynamk Announces Advisory Team
Kevin Bailey, PhD
Barry Buckland, PhD
Anthony Maddaluna
Gustavo Mahler, PhD
Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science tools and service providers, announces their all-star list of advisors. Dynamk has paved the way for startups with disruptive technologies and services to gain vital capital to reach the next phase. Dynamk’s partners have leveraged its network of fellow entrepreneurs, industry thought leaders and disrupters in creating a team of advisors to help ensure sound strategic decisions aimed at maximizing returns for investors.
When assembling the team, Dynamk sought domain experts with deep technical knowledge, a proven track record of successful businesses, and most of all, a keen sense of where the industry is trending. The advisor list is a who’s who of widely respected experts in their field:
· Kevin Bailey, PhD.; Former VP, Process Development and Preclinical Manufacturing, Regeneron. Kevin brings his experience in preclinical manufacturing and process development areas where he has had extensive experience developing new products, processes and evaluating new technologies.
· Barry Buckland, PhD.; CEO, BiologicB, LLC and former VP, Bioprocess R&D, Merck and Co., Inc. In addition to his years of experience in bioscience and discovery, Barry is a constant source of early stage technologies through his vast industry network and as President of Engineering Conferences International (ECI).
· Anthony Maddaluna; Former President, Pfizer Global Supply. Anthony brings his experience in diligence and evaluating the merits of new technologies to be deployed into cGMP manufacturing operations.
· Gustavo Mahler, PhD.; CEO, CMC Biologics / AGC Asahi Glass. Gustavo is an expert in biologic development and manufacturing; in his most recent role, he is directly responsible for evaluating and implementing cutting edge technologies.
Barry Buckland commented, “Dynamk Capital has an important role to fill in the Biopharmaceutical industry by making strategic investments to accelerate commercialization of innovative tools and technologies.“
General Partner Daniella Kranjac commented, “The team of advisors will bring insights on best practices and operational excellence needed for early stage companies. They are also well aware of all the key players likely for exiting to and how innovative technologies can fill gaps in their portfolios. This will ensure that companies which are highly likely to succeed are brought into the fund and will be best positioned to exit with maximum returns.”
Kevin Bailey commented, “Dynamk Capital has the rare opportunity to help accelerate research, development and manufacturing in the biopharma industry by identifying companies with disruptive new technologies and facilitating getting them into the hands of those who will bring new products and hope to patients.”